Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

<< Previous
Bullboard Posts
Next >>
Post by GoldenArmon Feb 09, 2022 1:01pm
176 Views
Post# 34413146

Good addition should expand and accelerate sales

Good addition should expand and accelerate salesBrad Davis will assume the role of Chief Commercial Officer and head a leadership team responsible for global commercialization and expanding U.S. commercial operations. He will report to Louis Laflamme, OpSens President and CEO.

This guy has great contacts.

Brad Davis formerly served as Vice President, Global Marketing and Health Care Economics & Reimbursement at Cardiovascular Systems, Inc. (CSI). During his nearly seven-year tenure at CSI, the company tripled coronary atherectomy revenue and grew peripheral atherectomy revenue faster than market to achieve U.S. atherectomy market share leadership, while simultaneously expanding into new product categories. Prior to CSI, Brad held numerous commercial roles of increasing responsibility at Guidant and Boston Scientific from 2000 to 2014. Brad holds an MBA in Marketing and Strategic Management from the Kelley School of Business, Indiana University, and a BS in Business Administration from the University of Kansas.
<< Previous
Bullboard Posts
Next >>